Newsfeeds - Spark Newswire

1 minute read

Earnings

Recap: Cellectar Biosciences Q1 Earnings

Today, 7:08 PM

Cellectar Biosciences (NASDAQ:CLRB) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Cellectar Biosciences reported in-line EPS of $-0.1 versus an estimate of $-0.1.

CLRB

1 minute read

Cellectar Biosciences Q1 EPS $(0.10) Up From $(0.13) YoY

By Benzinga Newsdesk

Today, 7:08 PM

Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.10) per share. This is a 23.08 percent increase over losses of $(0.13) per share from the same period last year.

CLRB

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s Intraday Session

By Benzinga Insights

Today, 7:08 PM

Gainers

BFRI

1 minute read

Here’s Why Cellectar Biosciences Shares Are Rising

By Henry Khederian

Today, 7:08 PM

Cellectar Biosciences Inc (NASDAQ: CLRB) shares are trading higher by 12.1% at $0.61 after the company reported better-than-expected fourth-quarter EPS results. Cellectar Biosciences beat estimated earnings by 10.0%, reporting an EPS loss of 9 cents versus an estimate of a loss of 1

CLRB

30 minute read

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 7:08 PM

During Tuesday's trading, 505 companies set new 52-week lows.

ACRX

2 minute read

Movers

12 Health Care Stocks Moving In Friday’s After-Market Session

By Benzinga Insights

Today, 7:08 PM

Gainers Enveric Biosciences (NASDAQ:ENVB) stock rose 6.8% to $0.64 during Friday's after-market session. The market value of their outstanding shares is at $20.8 million.

ACCD

2 minute read

Kazia Therapeutics Named John Friend, MD, as Chief Medical Officer

By Charles Gross

Today, 7:08 PM

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD, as Chief Medical Officer. In this role, Dr.

CLRB

1 minute read

Cellectar Biosciences Q3 EPS $(0.10) Up From $(0.15) YoY

By Benzinga Newsdesk

Today, 7:08 PM

Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.10) per share. This is a 33.33 percent increase over losses of $(0.15) per share from the same period last year.

CLRB

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s After-Market Session

By Benzinga Insights

Today, 7:08 PM

Gainers

BLPH

1 minute read

Cellectar Bio’s Iopofosine Data Shows Favorable Safety Profile In Head & Neck Cancer

By Vandana Singh

Today, 7:08 PM

Cellectar Biosciences Inc (NASDAQ:CLRB) has completed part A portion of a safety and tolerability study of iopofosine I-131 (iopofosine) in combination…

CLRB